The Health Innovation Corridor
Europe has the science and cannot scale it. The Gulf has the capacity to scale and imports too much of the science. Neither gap is permanent, and neither region closes it alone.
I wrote this paper because the conversation between Europe and the Gulf on health innovation has become very good at goodwill and very bad at mechanism. There is no shortage of forums, delegations or memoranda. There is a shortage of anything that carries a technology from a validated scientific result to a patient treated differently.
The diagnosis usually offered for Europe is a funding gap. I think that is the wrong target. Early-stage capital exists on the continent, and late-stage capital increasingly does too. What fails is the middle: the stretch from Series A through early clinical development, where costs rise, risk stays high, and no investor base is willing to carry the same company across successive rounds. Founders rebuild their syndicates at every stage, and eventually the rational move is to leave. Europe does not lose because its science is weak. It loses because its science leaves.
The Gulf’s constraint is the mirror image. Capital, decision-making speed and population-scale genomic data are all present at a level few regions can match. What is comparatively scarce is a validated, de-risked pipeline to point them at.
The paper argues that these are not competing strengths but complementary deficits, and that the answer is not more market access. It is a shared institutional capacity: a common qualification framework, a route to a first paying customer through procurement rather than another grant, a mapped regulatory pathway, blended capital, and a data compact under which models and results travel while raw data stays in its own jurisdiction.
It also argues for where to begin. Central and Eastern Europe is where the European paradox is sharpest, and where treatment-naive patient cohorts and competitive trial capacity pair naturally with the Gulf’s genomic reference data. That combination is something neither region holds alone.
The full argument, including the operating model, the priority sectors, a 24-month pilot and the failure modes I think are most likely, is in the paper below.
DOI: 10.2139/ssrn.7152978